Compare · AZN vs PTPI
AZN vs PTPI
Side-by-side comparison of AstraZeneca PLC (AZN) and Petros Pharmaceuticals Inc. (PTPI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and PTPI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $576.71B, about 17210.6x PTPI ($33.5M).
- Over the past year, AZN is down 1.2% and PTPI is up 0.0% - PTPI leads by 1.2 points.
- AZN has been more active in the news (25 items in the past 4 weeks vs 5 for PTPI).
- AZN has more recent analyst coverage (25 ratings vs 0 for PTPI).
- Company
- AstraZeneca PLC
- Petros Pharmaceuticals Inc.
- Price
- $186.00+2.32%
- $0.06-50.66%
- Market cap
- $576.71B
- $33.5M
- 1M return
- +0.65%
- +0.00%
- 1Y return
- -1.21%
- +0.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 25
- 5
- Recent ratings
- 25
- 0
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Petros Pharmaceuticals Inc.
Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest PTPI
- Officer Boctor Fady was granted 375,000 shares, increasing direct ownership by 72% to 894,986 units (SEC Form 4)
- Director Bernstein Bruce was granted 1,875,000 shares, increasing direct ownership by 99% to 3,762,334 units (SEC Form 4)
- Director Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 99% to 8,790,450 units (SEC Form 4)
- Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Petros Pharmaceuticals Inc.
- SEC Form 10-K filed by Petros Pharmaceuticals Inc.
- SEC Form NT 10-K filed by Petros Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.
- Officer Boctor Fady was granted 500,000 shares, increasing direct ownership by 2,502% to 519,986 units (SEC Form 4)
- Director Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 10,816% to 4,415,450 units (SEC Form 4)